Navrogen Announces Publication of NAV-001 Antibody-Drug Conjugate Development and Efficacy in Humoral Immunosuppressed Cancers
CHEYNEY, PA — Navrogen, Inc. announced a publication describing new criteria for antibody-drug conjugate (ADC) development and preclinical efficacy of NAV-001 ADC against mesothelin-expressing tumor types. The publication is presented …
Navrogen Announces Publication of NAV-001 Antibody-Drug Conjugate Development and Efficacy in Humoral Immunosuppressed Cancers Read More